These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30219823)

  • 1. Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.
    Hsue PY; Ribaudo HJ; Deeks SG; Bell T; Ridker PM; Fichtenbaum C; Daar ES; Havlir D; Yeh E; Tawakol A; Lederman M; Currier JS; Stein JH
    Clin Infect Dis; 2019 May; 68(11):1877-1886. PubMed ID: 30219823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV.
    Gingrich D; Deitchman AN; Kantor A; Huang L; Stein JH; Currier JS; Hsue PY; Ribaudo HJ; Aweeka FT;
    J Acquir Immune Defic Syndr; 2020 Dec; 85(5):651-658. PubMed ID: 33177476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate.
    Stein JH; Yeh E; Weber JM; Korcarz C; Ridker PM; Tawakol A; Hsue PY; Currier JS; Ribaudo H; Mitchell CKC
    Arterioscler Thromb Vasc Biol; 2018 Dec; 38(12):2870-2878. PubMed ID: 30571173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.
    Dubé MP; Chan ES; Lake JE; Williams B; Kinslow J; Landay A; Coombs RW; Floris-Moore M; Ribaudo HJ; Yarasheski KE
    Clin Infect Dis; 2019 Sep; 69(7):1165-1172. PubMed ID: 30535188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study).
    Serrano-Villar S; de Lagarde M; Vázquez-Castellanos J; Vallejo A; Bernadino JI; Madrid N; Matarranz M; Díaz-Santiago A; Gutiérrez C; Cabello A; Villar-García J; Blanco JR; Bisbal O; Sainz T; Moya A; Moreno S; Gosalbes MJ; Estrada V
    Clin Infect Dis; 2019 Jan; 68(1):120-130. PubMed ID: 29788075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
    Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
    Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lalama C; Schackman BR; Meyer WA; Acosta EP; Schouten J; Squires KE; Pilcher CD; Murphy RL; Koletar SL; Carlson M; Reichman RC; Bastow B; Klingman KL; Kuritzkes DR;
    JAMA; 2006 Aug; 296(7):769-81. PubMed ID: 16905783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
    Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
    Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial.
    Launay O; van der Vliet D; Rosenberg AR; Michel ML; Piroth L; Rey D; Colin de Verdière N; Slama L; Martin K; Lortholary O; Carrat F;
    JAMA; 2011 Apr; 305(14):1432-40. PubMed ID: 21486976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial.
    Kasang C; Kalluvya S; Majinge C; Kongola G; Mlewa M; Massawe I; Kabyemera R; Magambo K; Ulmer A; Klinker H; Gschmack E; Horn A; Koutsilieri E; Preiser W; Hofmann D; Hain J; Müller A; Dölken L; Weissbrich B; Rethwilm A; Stich A; Scheller C
    PLoS One; 2016; 11(1):e0146678. PubMed ID: 26812052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
    Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
    PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation.
    Macatangay BJC; Jackson EK; Abebe KZ; Comer D; Cyktor J; Klamar-Blain C; Borowski L; Gillespie DG; Mellors JW; Rinaldo CR; Riddler SA
    J Infect Dis; 2020 Apr; 221(10):1598-1606. PubMed ID: 31282542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
    Montaner J; Yeni P; Clumeck NN; Fätkenheuer G; Gatell J; Hay P; Seminari E; Peeters MP; Schöller-Gyüre M; Simonts M; Woodfall B;
    Clin Infect Dis; 2008 Oct; 47(7):969-78. PubMed ID: 18764771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
    Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
    Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.
    Dubé MP; Komarow L; Fichtenbaum CJ; Cadden JJ; Overton ET; Hodis HN; Currier JS; Stein JH;
    Clin Infect Dis; 2015 Sep; 61(5):840-9. PubMed ID: 25979307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
    ; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
    Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.